Argitalpenak (70) ALFONSO GÓMEZ DE ITURRIAGA PIÑA argitalpenak

2024

  1. Criteria and indicators to evaluate quality of care in genitourinary tumour boards

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1639-1646

  2. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities

    Clinical and Translational Radiation Oncology, Vol. 45

  3. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

    European urology oncology, Vol. 7, Núm. 3, pp. 462-468

  4. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach

    Radiotherapy and Oncology, Vol. 190

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

    Clinical and Translational Radiation Oncology, Vol. 43

  4. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer

    Clinical and Translational Radiation Oncology, Vol. 41

  5. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

  6. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer

    Radiotherapy and Oncology, Vol. 186

2022

  1. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

    Radiotherapy and Oncology, Vol. 172, pp. 1-9

  2. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

    Frontiers in Oncology, Vol. 12

  3. Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy

    Reports of Practical Oncology and Radiotherapy, Vol. 27, Núm. 3, pp. 428-439

  4. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

    Radiotherapy and Oncology, Vol. 176, pp. 199-207

  5. Should brachytherapy be added to external beam radiotherapy for prostate cancer?

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 23-25

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Adjuvant versus early salvage radiotherapy for prostate cancer patients: Time to move on

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 6, pp. 351-356

  3. Extreme hypofractionation with sbrt in localized prostate cancer

    Current Oncology, Vol. 28, Núm. 4, pp. 2933-2949

  4. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

  5. Salvage local treatment for localized radio-recurrent prostate cancer: A narrative review and future perspectives

    Future Oncology, Vol. 17, Núm. 31, pp. 4207-4219